Your session is about to expire
← Back to Search
Other
LY3857210 for Chronic Lower Back Pain
Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, up to week 12
Awards & highlights
Study Summary
This trial tests a new drug to ease chronic back pain. It's part of a protocol to develop better pain treatments.
Eligible Conditions
- Chronic Lower Back Pain
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, up to week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, up to week 12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
Secondary outcome measures
Change from Baseline for Overall Improvement as Measured by Patient's Global Impression of Change
Change from Baseline for Worst Pain Intensity as Measured by NRS
Change from Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L)
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3857210Experimental Treatment1 Intervention
Participants will receive LY3857210
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3857210
2022
Completed Phase 2
~430
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,783 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,542 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger